Literature DB >> 21329756

Cimetidine: an anticancer drug?

Martina Kubecova1, Katarina Kolostova, Daniela Pinterova, Grzegorz Kacprzak, Vladimir Bobek.   

Abstract

Cimetidine, H(2) receptor antagonists, is commonly prescribed for gastric and duodenal ulcer disease. Additionally, cimetidine has been shown to have anticancer effects. This review describes the mechanism of antitumor action of cimetidine including its ability to interfere with tumor cell adhesion, angiogenesis and proliferation; its effect on the immune system; as well as inhibition of postoperative immunosuppression. Its anticancer effect is also compared to that of the other H(2) receptor antagonists as well as outcomes of cimetidine in clinical studies in cancer patients.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21329756     DOI： 10.1016/j.ejps.2011.02.004

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN： 0928-0987            Impact factor:   4.384


  24 in total

Review 1.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

2.  Pharmacological reports about gastroprotective effects of methanolic extract from leaves of Solidago chilensis (Brazilian arnica) and its components quercitrin and afzelin in rodents.

Authors:  Mariel de Barros; Luisa Mota da Silva; Thaise Boeing; Lincon Bordignon Somensi; Benhur Judah Cury; Ligia de Moura Burci; José Roberto Santin; Sérgio Faloni de Andrade; Franco Delle Monache; Valdir Cechinel-Filho
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-13       Impact factor: 3.000

Review 3.  Histamine receptors and cancer pharmacology: an update.

Authors:  Noelia A Massari; Melisa B Nicoud; Vanina A Medina
Journal:  Br J Pharmacol       Date:  2018-12-13       Impact factor: 8.739

4.  Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma.

Authors:  Silvana Papagerakis; Emily Bellile; Lisa A Peterson; Maria Pliakas; Katherine Balaskas; Sara Selman; David Hanauer; Jeremy M G Taylor; Sonia Duffy; Gregory Wolf
Journal:  Cancer Prev Res (Phila)       Date:  2014-12

5.  Repurposing cimetidine for cholangiocarcinoma: Antitumor effects in vitro and in vivo.

Authors:  Paweena Dana; Kulthida Vaeteewoottacharn; Ryusho Kariya; Kouki Matsuda; Sopit Wongkham; Seiji Okada
Journal:  Oncol Lett       Date:  2017-01-02       Impact factor: 2.967

6.  Anti-neoplastic action of Cimetidine/Vitamin C on histamine and the PI3K/AKT/mTOR pathway in Ehrlich breast cancer.

Authors:  Sherihan Salaheldin Abdelhamid Ibrahim; Sarah A Abd El-Aal; Ahmed M Reda; Samar El Achy; Yasmine Shahine
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

7.  Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice.

Authors:  Y Edrei; E Gross; N Corchia; R Abramovitch
Journal:  Br J Cancer       Date:  2012-07-17       Impact factor: 7.640

8.  EHR-based phenome wide association study in pancreatic cancer.

Authors:  Tomasz Adamusiak; Mary Shimoyama
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2014-04-07

9.  Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.

Authors:  Vidula Sukhatme; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme; Pan Pantziarka
Journal:  Ecancermedicalscience       Date:  2015-08-27

10.  Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.

Authors:  Pan Pantziarka; Vidula Sukhatme; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2015-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.